In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae
- 1 June 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (6), 1515-1516
- https://doi.org/10.1128/aac.42.6.1515
Abstract
The in vitro activities of HMR 3647, roxithromycin, erythromycin, and azithromycin against 19 strains of Chlamydia pneumoniae were tested. The MIC at which 90% of the isolates are inhibited and the minimum bactericidal concentration at which 90% of the isolates are killed of HMR 3647 were 0.25 μg/ml (range, 0.015 to 2 μg/ml). Nine recently obtained clinical isolates from children with pneumonia were more susceptible (MICs, 0.015 to 0.0625 μg/ml) than older strains that had been passaged more extensively.Keywords
This publication has 5 references indexed in Scilit:
- In vitro activity of trovafloxacin against Chlamydia pneumoniaeAntimicrobial Agents and Chemotherapy, 1997
- In-vitro activity of ketolides against mycoplasmasJournal of Antimicrobial Chemotherapy, 1997
- Antimicrobial activity of RU-66647, a new ketolideDiagnostic Microbiology and Infectious Disease, 1997
- In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniaeAntimicrobial Agents and Chemotherapy, 1994
- In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniaeAntimicrobial Agents and Chemotherapy, 1992